“GLP-1s cause thyroid cancer.”
What the evidence shows
GLP-1 drugs carry an FDA boxed warning because, in rodents, semaglutide caused dose- and duration-dependent thyroid C-cell tumors, and the drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. The largest human study to date — a Scandinavian cohort of about 145,000 GLP-1 users versus 290,000 comparators (BMJ, 2024) — found no substantial increase in thyroid cancer (hazard ratio 0.93, 95% CI 0.66–1.31), and multi-country cohort data are broadly consistent.
What we still don’t know
Whether the rodent C-cell tumor effect translates to humans is genuinely unknown, and the human cohorts cannot fully exclude a small increase in a rare cancer subtype or rule out longer-term effects beyond a few years of follow-up. A minority of observational analyses have reported elevated risk signals, so the question is not entirely closed.
Why the claim misleads
The flat statement "GLP-1s cause thyroid cancer" promotes a rodent finding and a precautionary warning into a proven human cause-and-effect, which the best available human evidence does not support. It also collapses a specific, rare cancer subtype (medullary/C-cell) and a real contraindication for high-risk individuals into a blanket scare for everyone — the kind of social-media-as-evidence overstatement Chapter 20 warns against.
Graded by The Peptide Era · evidence, not hype